Ekso Bionics Holdings Inc (CHRN) Stock Analysis
Verdict: AVOID
Negative 34% growth and massive earnings misses collide with a liquidity crisis, making the 225x P/S valuation fundamentally unsustainable.
Investment score: 28/100
Analysis as of
Is Ekso Bionics Holdings Inc stock worth reviewing? AI model thesis
The AI model identifies CHRN as a high-risk entity with failing fundamentals and extreme valuation disconnects. Avoid until the balance sheet is restructured.
7-factor investment score
- Valuation: 10/100 (weight 20%)
- Financial Health: 15/100 (weight 15%)
- Technical Momentum: 25/100 (weight 15%)
- Earnings Quality: 5/100 (weight 15%)
- Insider Sentiment: 50/100 (weight 10%)
- Analyst Consensus: 70/100 (weight 10%)
- Risk-Adjusted Return: 20/100 (weight 15%)
Ekso Bionics Holdings Inc opportunities and risks
What speaks for CHRN
- Niche Market Leadership in Exoskeletons
What speaks against CHRN
- Imminent Liquidity Crunch
Peers and competitors
| Ticker | P/E | P/S | EV/EBITDA | Gross margin | Net margin | FCF yield |
|---|---|---|---|---|---|---|
| ITGR | 33.9x | 2.3x | 17.9x | 23.7% | 7.0% | 2.6% |
| IRTC | n/a | 5.0x | 227.9x | 71.5% | -1.7% | 1.0% |
| TMDX | 20.0x | 4.6x | 28.8x | 58.7% | 22.7% | 2.6% |
| PLSE | n/a | 2424.4x | n/a | -21.6% | -6755.8% | -2.1% |
| BFLY | n/a | 23.8x | n/a | 51.1% | -68.9% | -1.4% |
| Peer median | n/a | 5.0x | 17.9x | 51.1% | -1.7% | 1.0% |
Frequently asked questions about Ekso Bionics Holdings Inc (CHRN)
Is CHRN stock a good investment?
The cached TradeMates AI model rates Ekso Bionics Holdings Inc as AVOID with an investment score of 28/100. The AI model identifies CHRN as a high-risk entity with failing fundamentals and extreme valuation disconnects. Avoid until the balance sheet is restructured. This is algorithmic model output, not personal investment advice.
Is CHRN stock a buy?
The TradeMates model verdict for CHRN is AVOID with an investment score of 28/100. Treat this as a model signal to review, not a personal buy recommendation.